查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578806

PDGFR 抑制剂市场：按适应症、药物类型、给药方法和最终用户 - 2025-2030 年全球预测

PDGFR Inhibitor Market by Therapeutic Indication (Gastrointestinal Stromal Tumors, Glioblastoma, Leukemia), Drug Type (Combination Therapy, Monotherapy), Mode Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

PDGFR抑制剂市场2023年估值为32.1亿美元，预计2024年将达34.3亿美元，复合年增长率为5.21%，到2030年将达到45.9亿美元。

PDGFR（血小板源性生长因子受体）抑制剂的范围和定义涉及针对PDGFR讯号途径。该途径在细胞增殖、存活和迁移中发挥关键作用，为治疗方法癌症和纤维化疾病等疾病提供了一条有前景的途径。需要这些抑制剂是因为它们具有治疗神经胶母细胞瘤、前列腺癌等恶性和皮肤纤维肉瘤原形瘤等罕见疾病的潜力。透过抑制讯号途径，这些药物抑制肿瘤生长和转移，这是它们的主要用途。 PDGFR 抑制剂的最终用途广泛应用于製药和生物技术领域，以及在临床试验和治疗环境中使用这些药物的医院和研究机构。

主要市场统计
基准年[2023] 32.1亿美元
预测年份 [2024] 34.3亿美元
预测年份 [2030] 45.9亿美元
复合年增长率（%） 5.21%

根据市场洞察，成长的主要驱动力是肿瘤疾病盛行率的增加、研发投入的高额以及对新型癌症治疗方法的迫切需求。个人化医疗的技术进步和趋势将进一步推动市场扩张。新的商机在于联合治疗的开发和靶向抗药性肿瘤基因组学。公司可以透过投资与生物技术公司的合作研究和策略联盟来利用这些优势。然而，严格的监管核准、高昂的开发成本和潜在的副作用构成了重大挑战，限制了市场成长。此外，替代疗法的竞争压力和不断增长的肿瘤抗药性需要持续的技术创新。

为了促进创新和研究，探索分子机制和新型生物标记以提高 PDGFR 抑制剂的疗效和安全性至关重要。市场开拓洞察揭示了开发具有低毒性和更高生物有效性度的高选择性抑制剂的重点。市场竞争激烈，主要企业不断透过策略合併、收购和联盟来寻求优势，以加强其产品线。在此动态下，PDGFR 抑制剂市场持续稳定成长，为那些巧妙驾驭市场复杂性并利用新兴趋势和未满足的医疗需求的公司提供了巨大的成长机会。

市场动态：揭示快速发展的 PDGFR 抑制剂市场的关键市场洞察

PDGFR 抑制剂市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

波特五力：驾驭 PDGFR 抑制剂市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 PDGFR 抑制剂市场的外部影响

外部宏观环境因素在塑造 PDGFR 抑制剂市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解PDGFR抑制剂市场的竞争格局

PDGFR 抑制剂市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：PDGFR 抑制剂市场供应商的绩效评估

FPNV定位矩阵是评估PDGFR抑制剂市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划 PDGFR 抑制剂市场的成功之路

PDGFR 抑制剂市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料以及对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • PDGFR抑制剂应用的广泛研发拓展了临床应用
      • 增加监管支持并加快关键市场新 PDGFR 抑制剂的核准
      • 製药巨头之间的策略联盟促进PDGFR抑制剂的广泛分布
      • 药物输送系统的技术进步可提高 PDGFR 抑制剂的疗效和患者依从性
    • 抑制因素
      • 医护人员对 PDGFR 抑制剂的益处和用途缺乏认识
      • 分销挑战限制了 PDGFR 抑制剂在新兴市场的可用性
    • 机会
      • 合作推进 PDGFR 抑制剂开发的生物製药进展
      • 在全球扩大 PDGFR 抑制剂的临床试验，以满足未满足的医疗需求
      • 加速罕见疾病核准的监管奖励
    • 任务
      • 来自替代疗法的竞争压力降低了 PDGFR 抑制剂的市场占有率
      • 智慧财产权和专利纠纷阻碍PDGFR抑制剂的市场动态
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境的

第六章 PDGFR 抑制剂市场待遇：依适应症分类

  • 胃肠道基质肿瘤
  • 神经胶母细胞瘤
  • 白血病

第七章 PDGFR 抑制剂市场：依药物类型

  • 联合治疗
  • 单一疗法

第八章 PDGFR 抑制剂市场：依管理方法分类

  • 静脉
  • 口服

第 9 章 PDGFR 抑制剂市场：依最终用户分类

  • 医院
  • 研究/学术机构
  • 专科诊所

第十章美洲PDGFR抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太PDGFR抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲PDGFR抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Deciphera Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Incyte Corporation
  • MedChemExpress
  • Merck KGaA
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • R&D Systems, Inc.
  • Santa Cruz Biotechnology, Inc.
  • TargetMol Chemicals Inc.
  • Tocris Bioscience
  • Zai Lab Limited
Product Code: MRR-9A6A6F297DE6

The PDGFR Inhibitor Market was valued at USD 3.21 billion in 2023, expected to reach USD 3.43 billion in 2024, and is projected to grow at a CAGR of 5.21%, to USD 4.59 billion by 2030.

The scope and definition of PDGFR (Platelet-Derived Growth Factor Receptor) inhibitors revolve around targeting the PDGFR signaling pathway, which is crucial for cell proliferation, survival, and migration, thus providing treatment avenues for diseases like cancer and fibrotic conditions. These inhibitors are necessary due to their therapeutic potential in managing malignancies such as glioblastomas, prostate cancer, and rarer conditions like dermatofibrosarcoma protuberans. By impeding the signaling pathways, these drugs curb tumor growth and metastasis, which are primary applications. The end-use scope of PDGFR inhibitors predominantly spans the pharmaceutical and biotechnology sectors, alongside hospitals and research institutions that employ these drugs in clinical trials and therapeutic settings.

KEY MARKET STATISTICS
Base Year [2023] USD 3.21 billion
Estimated Year [2024] USD 3.43 billion
Forecast Year [2030] USD 4.59 billion
CAGR (%) 5.21%

Market insights indicate that the growth is primarily driven by the increasing prevalence of oncological disorders, significant R&D investments, and the urgent need for novel cancer therapies. Technological advancements and personalized medicine trends further catalyze market expansion. Emerging opportunities lie within the development of combination therapies and targeting resistant tumor genomics. Companies can capitalize on these by investing in collaborative research and strategic alliances with biotech firms. However, stringent regulatory approvals, high development costs, and potential side effects pose significant challenges, restricting market growth. There is also the competitive pressure from alternative therapies and resistance development in tumors, which necessitates continuous innovation.

For fostering innovation and research, exploring molecular mechanisms and novel biomarkers for better efficacy and safety profiles of PDGFR inhibitors is paramount. Market growth insight reveals a focus on developing less toxic, more selective inhibitors with enhanced bioavailability. The nature of the PDGFR inhibitor market is competitive, with key players continuously seeking edges through strategic mergers, acquisitions, and collaborations to boost their pipelines. With these dynamics, the PDGFR inhibitor market remains poised for steady growth, offering significant opportunities for companies that skillfully navigate the market's complexities and capitalize on emerging trends and unmet medical needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving PDGFR Inhibitor Market

The PDGFR Inhibitor Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expanding clinical applications owing to substantial research and development in PDGFR inhibitor uses
    • Enhanced regulatory support and fast-track approvals for new PDGFR inhibiting drugs in key markets
    • Strategic collaborations between pharmaceutical giants aiding in extensive distribution of PDGFR inhibitors
    • Technological advancements in drug delivery systems improving the efficacy and patient compliance of PDGFR inhibitors
  • Market Restraints
    • Lack of awareness among healthcare professionals about the benefits and uses of PDGFR inhibitors
    • Limited availability of PDGFR inhibitors in emerging markets due to distribution challenges
  • Market Opportunities
    • Collaborative partnerships driving biopharmaceutical advancements in PDGFR inhibitor development
    • Expanding global clinical trials for PDGFR inhibitors to address unmet medical needs
    • Regulatory incentives for accelerated PDGFR inhibitor approvals in rare diseases
  • Market Challenges
    • Competitive pressure from alternative therapies reducing market share for PDGFR inhibitors
    • Intellectual property and patent disputes hindering market dynamics for PDGFR inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the PDGFR Inhibitor Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the PDGFR Inhibitor Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the PDGFR Inhibitor Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the PDGFR Inhibitor Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the PDGFR Inhibitor Market

A detailed market share analysis in the PDGFR Inhibitor Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the PDGFR Inhibitor Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the PDGFR Inhibitor Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the PDGFR Inhibitor Market

A strategic analysis of the PDGFR Inhibitor Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the PDGFR Inhibitor Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Deciphera Pharmaceuticals, Inc., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline, Incyte Corporation, MedChemExpress, Merck KGaA, Novartis Pharmaceuticals Corporation, Pfizer Inc., R&D Systems, Inc., Santa Cruz Biotechnology, Inc., TargetMol Chemicals Inc., Tocris Bioscience, and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the PDGFR Inhibitor Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Indication, market is studied across Gastrointestinal Stromal Tumors, Glioblastoma, and Leukemia.
  • Based on Drug Type, market is studied across Combination Therapy and Monotherapy.
  • Based on Mode Of Administration, market is studied across Intravenous and Oral.
  • Based on End User, market is studied across Hospitals, Research & Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expanding clinical applications owing to substantial research and development in PDGFR inhibitor uses
      • 5.1.1.2. Enhanced regulatory support and fast-track approvals for new PDGFR inhibiting drugs in key markets
      • 5.1.1.3. Strategic collaborations between pharmaceutical giants aiding in extensive distribution of PDGFR inhibitors
      • 5.1.1.4. Technological advancements in drug delivery systems improving the efficacy and patient compliance of PDGFR inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness among healthcare professionals about the benefits and uses of PDGFR inhibitors
      • 5.1.2.2. Limited availability of PDGFR inhibitors in emerging markets due to distribution challenges
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative partnerships driving biopharmaceutical advancements in PDGFR inhibitor development
      • 5.1.3.2. Expanding global clinical trials for PDGFR inhibitors to address unmet medical needs
      • 5.1.3.3. Regulatory incentives for accelerated PDGFR inhibitor approvals in rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Competitive pressure from alternative therapies reducing market share for PDGFR inhibitors
      • 5.1.4.2. Intellectual property and patent disputes hindering market dynamics for PDGFR inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. PDGFR Inhibitor Market, by Therapeutic Indication

  • 6.1. Introduction
  • 6.2. Gastrointestinal Stromal Tumors
  • 6.3. Glioblastoma
  • 6.4. Leukemia

7. PDGFR Inhibitor Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Combination Therapy
  • 7.3. Monotherapy

8. PDGFR Inhibitor Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. PDGFR Inhibitor Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research & Academic Institutes
  • 9.4. Specialty Clinics

10. Americas PDGFR Inhibitor Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific PDGFR Inhibitor Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa PDGFR Inhibitor Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bayer AG
  • 2. Blueprint Medicines Corporation
  • 3. Boehringer Ingelheim International GmbH
  • 4. Bristol Myers Squibb
  • 5. Deciphera Pharmaceuticals, Inc.
  • 6. Eli Lilly and Company
  • 7. Exelixis, Inc.
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline
  • 11. Incyte Corporation
  • 12. MedChemExpress
  • 13. Merck KGaA
  • 14. Novartis Pharmaceuticals Corporation
  • 15. Pfizer Inc.
  • 16. R&D Systems, Inc.
  • 17. Santa Cruz Biotechnology, Inc.
  • 18. TargetMol Chemicals Inc.
  • 19. Tocris Bioscience
  • 20. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. PDGFR INHIBITOR MARKET RESEARCH PROCESS
  • FIGURE 2. PDGFR INHIBITOR MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PDGFR INHIBITOR MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PDGFR INHIBITOR MARKET DYNAMICS
  • TABLE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023